Redeye presents its preview for Devyser’s Q4 2025 report, due on February 12.
Redeye is encouraged by Tagmaster’s solid earnings beat in the fourth quarter.
Redeye considers I-Tech's Q4 report to be soft, although the company faced relatively high set expec...
Redeye comments on Transtema’s Q4 report, showing numbers aligning with the preliminary figures.
Redeye comments on Evolution’s Q4-results which were close to our forecasts, albeit with soft revenu...
Redeye comments on Dynavox’s Q4 report released earlier this morning, which delivered another set of...
Fiskars Q4 adjusted EBIT of EUR 32.8m came 7% (EUR 2.
Redeye comments on Freja’s Q4, showing solid numbers in line with the preliminary figures.
Redeye comments on Hexatronic’s Q4 report, showing solid overall numbers driven by a further acceler...
Redeye provides an update following Coffee Stain Group’s Q3 2025/2026 report, which delivered strong...
Redeye comments on Smart Eye’s acquisition of Sightic, which removes the most meaningful competitive...
Redeye provides an update following Q-linea’s Q4 2025 report.
* First signs of Swedish project market recovery * Could add ~15% of '25e EBITA N3Y * Ready for M&A,...
Redeye leaves a comment following OncoZenge’s announcement of the completed readout from its UCLA-le...
Redeye comments on Coffee Stain Group’s Q3 2025/2026 results, which were better than expected on bot...
Sleep Cycle’s Q4 report was in line with our top-line expectations but revealed a steeper-than-antic...
* Net sales SEK 557m, +5% vs ABGSCe, +4% vs Factset cons.
While the current valuation profile of Vitrolife requires more than the current stagnant growth prof...
Redeye updates its estimates and valuation after Lifco’s Q4 2025 report.
Redeye retains its positive view of Addnode following a solid Q4 report.
